AbbVie Inc. $ABBV Stock Position Raised by D.A. Davidson & CO.

D.A. Davidson & CO. boosted its stake in AbbVie Inc. (NYSE:ABBV) by 4.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 255,285 shares of the company’s stock after purchasing an additional 11,585 shares during the period. D.A. Davidson & CO.’s holdings in AbbVie were worth $66,780,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ABBV. State Street Corp boosted its stake in shares of AbbVie by 1.7% in the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after buying an additional 1,379,232 shares during the last quarter. Corient Private Wealth LP bought a new stake in shares of AbbVie in the second quarter worth $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after acquiring an additional 106,091 shares during the last quarter. Legal & General Group Plc purchased a new stake in AbbVie during the second quarter valued at $2,905,952,000. Finally, Deutsche Bank AG increased its position in AbbVie by 13.0% during the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after acquiring an additional 1,241,587 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Trading Down 0.1%

AbbVie stock opened at $286.10 on Thursday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $291.40. The firm has a market capitalization of $505.47 billion, a price-to-earnings ratio of 80.82, a P/E/G ratio of 1.30 and a beta of 0.24. The firm has a 50 day moving average of $268.20 and a 200 day moving average of $236.51.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts predict that AbbVie Inc. will post 13.92 EPS for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is 195.48%.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted a Biologics License Application to the FDA for etentamig, a monthly-dosed BCMA x CD3 bispecific antibody for adults with relapsed or refractory multiple myeloma. The Phase 3 CERVINO study reportedly delivered statistically significant improvements in overall response rate and progression-free survival versus standard therapies, adding a potential growth product to AbbVie’s oncology pipeline. AbbVie Submits BLA for Etentamig
• Positive Sentiment: AbbVie’s growth drivers remain in focus. Skyrizi and Rinvoq are expected to help offset Humira’s decline, while the FDA’s approval of a subcutaneous induction option for Skyrizi in Crohn’s disease could improve convenience and broaden adoption through at-home treatment. Skyrizi Crohn’s Disease Approval
• Neutral Sentiment: Investors are preparing for AbbVie’s third-quarter results, with attention on Skyrizi and Rinvoq sales, expense trends, updated guidance, and the sustainability of earnings growth. The company previously reported quarterly revenue and adjusted earnings above consensus expectations.
• Negative Sentiment: Analysts continue to debate whether ABBV is fully valued after a strong rally. Its elevated valuation leaves less room for disappointment, while rising expenses, softer estimates, and intensifying competition could pressure near-term results. AbbVie Patent Cliff Analysis
• Negative Sentiment: The company’s dividend appeal faces a longer-term test as investors seek evidence that Skyrizi and Rinvoq can replace lost Humira revenue and support continued payout growth. High Treasury yields also make income-oriented stocks compete harder for investor capital.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ABBV shares. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Morgan Stanley boosted their price target on AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Leerink Partners upped their price target on shares of AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Cantor Fitzgerald upped their price target on shares of AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. Finally, UBS Group increased their price objective on shares of AbbVie from $260.00 to $275.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $279.86.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.